Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 229

1.

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MF, Bacher G, Holzhauer B, Bourne M, Mistry V, Pavord ID, Mansur AH, Wardlaw AJ, Siddiqui SH, Kay RA, Brightling CE.

Lancet Respir Med. 2016 Aug 5. pii: S2213-2600(16)30179-5. doi: 10.1016/S2213-2600(16)30179-5. [Epub ahead of print]

PMID:
27503237
2.

Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.

Pavord ID, Lettis S, Anzueto A, Barnes N.

Lancet Respir Med. 2016 Jul 22. pii: S2213-2600(16)30148-5. doi: 10.1016/S2213-2600(16)30148-5. [Epub ahead of print]

PMID:
27460163
3.

Emerging Biologics in Severe Asthma.

Pavord ID, Hilvering B, Shrimanker R.

Immunol Allergy Clin North Am. 2016 Aug;36(3):609-23. doi: 10.1016/j.iac.2016.04.001. Review.

PMID:
27401629
4.

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.

Trivedi A, Pavord ID, Castro M.

Lancet Respir Med. 2016 Jul;4(7):585-92. doi: 10.1016/S2213-2600(16)30018-2. Epub 2016 May 24. Review.

PMID:
27230825
5.

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.

Lancet Respir Med. 2016 Jul;4(7):549-56. doi: 10.1016/S2213-2600(16)30031-5. Epub 2016 May 10.

PMID:
27177493
6.

Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease.

Pavord ID, Agusti A.

Eur Respir J. 2016 May;47(5):1299-303. doi: 10.1183/13993003.00055-2016. No abstract available.

PMID:
27132257
7.

Exacerbations of COPD.

Pavord ID, Jones PW, Burgel PR, Rabe KF.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss:21-30. doi: 10.2147/COPD.S85978. eCollection 2016. Review.

8.

Morbidity associated with oral corticosteroids in patients with severe asthma.

Choo XN, Pavord ID.

Thorax. 2016 Apr;71(4):302-4. doi: 10.1136/thoraxjnl-2015-208242. Epub 2016 Feb 22. No abstract available.

PMID:
26903592
9.

Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.

Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC.

Chest. 2016 Aug;150(2):320-8. doi: 10.1016/j.chest.2016.01.026. Epub 2016 Feb 3.

PMID:
26851799
10.

Predictors of objective cough frequency in pulmonary sarcoidosis.

Sinha A, Lee KK, Rafferty GF, Yousaf N, Pavord ID, Galloway J, Birring SS.

Eur Respir J. 2016 May;47(5):1461-71. doi: 10.1183/13993003.01369-2015. Epub 2016 Feb 4.

PMID:
26846840
11.

Treatable traits: toward precision medicine of chronic airway diseases.

Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID.

Eur Respir J. 2016 Feb;47(2):410-9. doi: 10.1183/13993003.01359-2015.

PMID:
26828055
12.

Inhaled corticosteroid dose-response on blood eosinophils in asthma - Authors' reply.

Price DB, Pavord ID, Thomas M, Corrigan CJ, Wilson AM, Hillyer EV, Kerkhof M.

Lancet Respir Med. 2016 Jan;4(1):e1-2. doi: 10.1016/S2213-2600(15)00506-8. No abstract available.

PMID:
26762664
13.

Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.

Forrester DL, Knox AJ, Smyth AR, Barr HL, Simms R, Pacey SJ, Pavord ID, Honeybourne D, Dewar J, Clayton A, Fogarty AW.

Pediatr Pulmonol. 2016 Mar;51(3):253-7. doi: 10.1002/ppul.23370. Epub 2015 Dec 27.

PMID:
26709241
14.

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC.

Thorax. 2016 Feb;71(2):118-25. doi: 10.1136/thoraxjnl-2015-207021. Epub 2015 Nov 19.

15.

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.

Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID.

Lancet Respir Med. 2015 Nov;3(11):849-58. doi: 10.1016/S2213-2600(15)00367-7. Epub 2015 Oct 19.

PMID:
26493938
16.

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Catley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T.

Thorax. 2016 Feb;71(2):187-9. doi: 10.1136/thoraxjnl-2015-207326. Epub 2015 Jul 23. Review.

17.

Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function.

Bafadhel M, Haldar K, Barker B, Patel H, Mistry V, Barer MR, Pavord ID, Brightling CE.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 9;10:1075-83. doi: 10.2147/COPD.S80091. eCollection 2015.

18.

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.

Hilvering B, Xue L, Pavord ID.

Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Epub 2015 Apr 21. Review.

PMID:
25900924
19.

The asthmas in 2015 and beyond: a Lancet Commission.

Bush A, Kleinert S, Pavord ID.

Lancet. 2015 Apr 4;385(9975):1273-5. doi: 10.1016/S0140-6736(15)60654-7. No abstract available.

PMID:
25890896
20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk